title: Efficacy and safety of rufinamide in pediatric epilepsy.
abstract: Rufinamide is a novel anticonvulsant medication approved by the US Food and Drug Administration (FDA) in 2008 for the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older, based upon clinical trials demonstrating clinical efficacy and tolerability. Rufinamide is especially effective for tonic-atonic seizures in Lennox-Gastaut syndrome, but is subsequently proving to be safe and effective in clinical practice for a broad patient population with refractory epilepsy. Although further research and clinical experience is needed, rufinamide holds the promise to positively impact the care of children with epilepsy. In this review, we review the use of rufinamide in pediatric epilepsy, with a focus on efficacy and safety.
authors: Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
authors: David T
authors: DT
authors: Hsieh
authors: Elizabeth A
authors: EA
authors: Thiele
keywords: Lennox–Gastaut syndrome; anticonvulsants; epilepsy; rufinamide
references: Neuropediatrics. 2011 Feb;42(2):71-3
references: 21547865
references: Neurology. 1999 Jun 10;52(9):1882-7
references: 10371538
references: Epilepsy Behav. 2011 Feb;20(2):344-8
references: 21233024
references: Epilepsia. 2009 Aug;50(8):1899-909
references: 19490053
references: Eur J Paediatr Neurol. 2012 Sep;16(5):459-63
references: 22266062
references: Epilepsy Behav. 2011 Jul;21(3):282-4
references: 21620771
references: Neuropediatrics. 2011 Feb;42(1):28-9
references: 21557146
references: Epileptic Disord. 2011 Mar;13(1):18-21
references: 21393094
references: Pediatr Neurol. 2011 May;44(5):347-9
references: 21481742
references: Ann Neurol. 2009 May;65(5):510-9
references: 19475671
references: Epilepsy Res. 2001 Feb;43(2):115-24
references: 11164700
references: N Engl J Med. 1993 Jan 7;328(1):29-33
references: 8347179
references: Epilepsy Res. 2011 Jan;93(1):87-9
references: 21111576
references: J Child Neurol. 2009 Dec;24(12):1520-5
references: 19955344
references: Epilepsia. 2008 Jul;49(7):1213-20
references: 18325020
references: Epilepsia. 2008 Jul;49(7):1123-41
references: 18503564
references: Seizure. 2009 Oct;18(8):554-8
references: 19592271
references: Neurology. 2012 May 15;78(20):1548-54
references: 22573629
references: Neurology. 2008 May 20;70(21):1950-8
references: 18401024
references: Epilepsia. 2011 Aug;52 Suppl 5:10-20
references: 21790561
references: Cochrane Database Syst Rev. 2003;(3):CD003277
references: 12917958
references: Heart Rhythm. 2012 May;9(5):776-81
references: 22245794
references: Epilepsia. 2011 Aug;52 Suppl 5:3-9
references: 21790560
references: Epilepsy Res. 2012 Nov;102(1-2):94-9
references: 22677424
references: Epilepsia. 2006 Jul;47(7):1153-9
references: 16886978
references: Neurology. 2011 Oct 11;77(15):1473-81
references: 21956725
references: Allergol Immunopathol (Madr). 2013 Jan-Feb;41(1):68-9
references: 22306278
references: Seizure. 2012 May;21(4):288-91
references: 22421185
references: Epilepsia. 2011 Feb;52(2):234-42
references: 20887365
references: Seizure. 2010 Jan;19(1):23-30
references: 19948417
references: Neurology. 2004 Apr 27;62(8):1261-73
references: 15111660
references: Eur J Neurol. 2011 Feb;18(2):246-251
references: 20666837
references: N Engl J Med. 1997 Dec 18;337(25):1807-12
references: 9400037
references: Seizure. 2010 Nov;19(9):587-91
references: 20888268
references: Epilepsy Behav. 2009 Mar;14(3):491-5
references: 19162229
references: Pediatr Neurol. 2010 Sep;43(3):155-8
references: 20691934
references: Epilepsy Res. 2010 Feb;88(2-3):255-63
references: 20061123
references: Epilepsy Behav. 2010 Apr;17(4):546-8
references: 20185372
references: Acta Neurol Scand. 2010 Sep;122(3):202-8
references: 20199521